Introduction {#Sec1}
============

Colchicine is an anti-inflammatory agent which is widely used for the treatment of gout and also used extensively for familial Mediterranean fever, Behcet's disease and pericarditis. Its use in the management of gout has increased due to the widespread recommendation that it be used as a gout flare prophylaxis when urate-lowering therapy is initiated \[[@CR1]\]. It is used continuously for long periods of time in individuals with familial Mediterranean fever and Behcet's disease. However, due to its long historical use in medicine, it has not been subjected to the same registration trials that contemporary medicines require. There remains uncertainty regarding its use in certain risk groups including those with kidney and liver impairment, at higher doses, and with CYP3A4 inhibitors \[[@CR2]\]. It has previously been used in an intravenous preparation, but this is no longer used due to the adverse safety profile of this administration method \[[@CR3]\].

Although the adverse event profile of colchicine has been reported in various individual clinical trials and for single indications like pericarditis \[[@CR4]\], it has not been studied systematically to our knowledge. The aim of this study was to examine the adverse events of colchicine reported in randomised controlled trials using a systemic review and meta-analysis methodology.

Methods {#Sec2}
=======

This study was conducted according to a pre-defined protocol using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR5]\].

Search strategy {#Sec3}
---------------

Electronic databases (Cochrane Library, MEDLINE and EMBASE) were searched from inception to November 2019 using the following key words in the search term: colchicine AND ((randomised controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomised \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])). Bibliographical references from individual included studies and review articles were also hand-searched to identify additional relevant papers. All studies generated from the search were exported to RefWorks and screened to remove duplicates. Title and abstract screening, followed by full-text screening, was undertaken by a single reviewer (KA). Randomised controlled trials were included if they compared the effects of colchicine in patients, administered for any indication, to placebo or active comparators. Trials were included if they: had a double-blinded design, included oral colchicine in at least one of the treatment arms; involved adult participants; were published in the English language; and reported adverse event data in both the colchicine and comparator group(s) in relation to the number of participants with adverse events per group. Studies which reported the number of participants with adverse events resulting in study withdrawals and did not report the number of adverse events which occurred in the participants who remained in the study, were excluded. There was no publication date restriction. If multiple reports described the same trial, the most recent full-text publication was selected for inclusion.

Quality assessment {#Sec4}
------------------

Quality of all included studies was assessed independently by two reviewers (SS, KY) using the 6-item modified-Jadad scale which assesses reported randomisation, blinding, withdrawals, dropouts, inclusion/exclusion criteria, adverse events and the statistical analysis \[[@CR6]\]. The scale has a maximum score of 8 points, with low quality studies yielding scores of 0 to 3 and high-quality studies yielding a score of 4 to 8. Any disagreements in the quality assessment were resolved by discussion of the two reviewers. If necessary, a third reviewer (ND) was involved to reach consensus.

Data extraction {#Sec5}
---------------

Two reviewers (SS, KY) independently extracted data from the full-text studies using a Microsoft Excel extraction form. Any disagreements were resolved by consensus with a third reviewer (ND). Data extraction included publication details (author, year of publication, country of first author), disease state, participant characteristics (sample size, ethnicity, mean (SD) age and n % of male participants) and details of the trial (study design, length of follow up, primary outcome, interventions and dosages, intervention length). Extraction of data related to adverse events included the total number of participants with any adverse event per group and the total number of participants with each individual reported adverse event. Data for the number of deaths were extracted only if death was related to an adverse event (rather than worsening of disease).

Data-analyses {#Sec6}
-------------

For the purpose of data analysis, adverse events were grouped under eight pre-defined categories: diarrhoea, gastrointestinal events (including diarrhoea), liver events, haematology events, muscle-related events, sensory-related events (including neuropathy), infectious events, death and any adverse event. In situations when studies reported the number of participants with ≥ 2 individual adverse events which both came under the same category (i.e. "nausea" and "vomiting" which both come under the gastrointestinal event category), data from the adverse event with the highest number of participants was used for that category. Only studies which reported diarrhoea as a separate event were included in the diarrhoea category. Studies which reported diarrhoea as part of a combined event (i.e. 'diarrhoea or nausea') were included under the 'gastrointestinal events' category.

Meta-analyses were undertaken to determine the relative risk of adverse events in the colchicine group compared to the comparator groups (pooled comparators, placebo and active-comparators). Relative risk was calculated based on the number of participants with adverse events. Random effects models were used for all *I*^2^ values \> 0%. As caution is recommended when colchicine is used continuously in those with liver impairment, a sensitivity analysis was undertaken excluding the studies involving participants with cirrhosis or sclerosing cholangitis \[[@CR6]--[@CR11]\]. For the 'any adverse events' category, meta-analyses were also used to determine the effects of disease indication (liver diseases, gout, Behcet's and related conditions, pericarditis and related conditions and other), duration of exposure to the intervention (with subgroups defined as ≤ 2 weeks, 1 to 2 months, 3 to 5 months, 6 to 12 months and ≥ 24 months), the average daily dose of colchicine (with subgroups defined as \< 1 mg, 1 mg, \> 1 \< 2 mg, ≥ 2 mg) and the cumulative daily dose of colchicine (with subgroups defined as \< 50 mg, 50 to \< 100 mg, ≥ 100 mg to 300 mg, \> 600 mg). In papers which used different colchicine doses based on participant weight categories, the highest daily colchicine dose was used to determine that study's subgroup. Subgroup comparisons were made using the Phet statistic (the *P* value derived from the chi-square test of heterogeneity for subgroup differences).

All meta-analyses were undertaken in Review Manager 5.3 with an alpha level of 0.05. Only studies specifically reporting an adverse event as being present or absent were included in the meta-analyses. However, as this may over- or under-estimate the true occurrence of adverse events, the proportion of participants with specific adverse events was also computed in relation to the total number of participants included in all studies (i.e. if not reported, '0' events were considered to have occurred). These data were used for descriptive purposes only and not meta-analysed.

Results {#Sec7}
=======

Study characteristics {#Sec8}
---------------------

A total of 4915 studies were identified through the search following the deletion of duplicates (Fig. [1](#Fig1){ref-type="fig"}). After title and abstract screening, 70 full-text articles were assessed for eligibility. After the exclusion of 35 studies (reasons for exclusion are presented in Fig. [1](#Fig1){ref-type="fig"}), a total of 35 randomised-controlled double-blind studies were included in this review. The majority of studies were placebo-controlled (*n* = 30, 83%) and 5 (17%) studies were active-comparator controlled. The majority of studies were parallel-group designs and 4 studies \[[@CR12]--[@CR15]\] were cross-over designs. Fig. 1PRISMA flow chart

Quality assessment {#Sec9}
------------------

The results from the quality assessment are presented in Supplementary Figure [1](#MOESM1){ref-type="media"}. Overall, the modified-Jadad score indicated high quality (total score 4 to 8) for all studies. An appropriate method of randomisation and blinding was reported in 24 (69%) and 28 (80%) studies, respectively. Thirty (86%) studies provided an adequate description of withdrawals and dropouts and 33 (94%) provided a participant inclusion and exclusion criteria. The method used to assess adverse events was described by 22 (63%) studies and methods of statistical analysis by 32 (91%).

Participant characteristics {#Sec10}
---------------------------

Characteristics of participants in the included studies are shown in Table [1](#Tab1){ref-type="table"}. A number of disease states were studied including cirrhosis (*n* = 5 studies) \[[@CR6]--[@CR10]\], pericarditis (*n* = 4 studies) \[[@CR26], [@CR27], [@CR29], [@CR31]\], gout (*n* = 5 studies) \[[@CR15], [@CR18], [@CR34], [@CR38], [@CR39]\], knee osteoarthritis (*n* = 3 studies) \[[@CR16], [@CR20], [@CR30]\], Behcet's syndrome (*n* = 3 studies) \[[@CR21], [@CR32], [@CR40]\], psoriatic arthritis (*n* = 2 studies) \[[@CR13], [@CR36]\], post-pericardiotomy syndrome (*n* = 2 studies) \[[@CR25], [@CR28]\], chronic obstructive pulmonary disorder (*n* = 1 study) \[[@CR19]\], bare-metal stent restenosis (*n* = 1 study) \[[@CR22]\], metabolic syndrome (*n* = 1 study) \[[@CR23]\], lung resection surgery (*n* = 1 study) \[[@CR17]\], myocardial infarction (n = 1 study) \[[@CR37]\], familial Mediterranean fever (*n* = 1 study) \[[@CR12]\], asthma (*n* = 1 study) \[[@CR24]\], primary sclerosing cholangitis (*n* = 1 study) \[[@CR11]\], aphthous stomatitis (*n* = 1 study) \[[@CR33]\], allergic rhinitis (*n* = 1 study) \[[@CR14]\] and low back pain (*n* = 1 study) \[[@CR35]\]. Sample sizes ranged from 11 to 4745, with a pooled sample of 8659 adult participants. Mean age ranged from 27.0 to 69.1 years with most participants being male (73%). The inclusion and exclusion criteria reported by the included studies are shown in Supplementary Table [1](#MOESM1){ref-type="media"}. Table 1Characteristics of included studiesReferenceCountryDisease stateInterventionComparatorDaily dose of colchicine (mg)Cumulative dose of colchicine (mg)Length of interventionLength of follow-up for AE assessmentTotal sample sizeParticipant characteristicsAran 2011 \[[@CR16]\]USAKnee osteoarthritisColchicine, 0.5 mg twice dailyPlacebo1913 months3 months61Mean age 60.2 years0% malesBatezzati 2001 \[[@CR7]\]ItalyPrimary biliary cirrhosisColchicine, 1 mg daily + ursodeoxycholic acid, 250 mg dailyPlacebo + ursodeoxycholic acid, 250 mg daily1365010 years10 years44Mean age 56.5 years14% malesBessissow 2018 \[[@CR17]\]CanadaLung resection surgeryColchicine, 0.6 mg 3 times daily for first day, then twice dailyPlacebo1.2612.610 days30 days100Mean age 69 years45% malesBorstad 2004 \[[@CR18]\]USAChronic gouty arthritisColchicine, 0.6 mg twice dailyPlacebo1.2219.06 months6 months43Mean age 63 years86% malesCohen 1991 \[[@CR19]\]USACOPD in ex-cigarette smokersColchicine, 0.6 mg 3 times dailyPlacebo1.825.22 weeks2 weeks16Mean age 65.9 years% males NRCortez-Pinto 2002 \[[@CR8]\]PortugalAlcoholic cirrhosisColchicine, 1 mg daily, 5 days/weekPlacebo0.714901.341.5 months (mean)41.5 months (mean)55Mean age 53.8 years89% malesDas 2002 \[[@CR20]\]IndiaKnee osteoarthritisColchicine, 0.5 mg twice daily + Piroxicam, 20 mg once dailyPlacebo + Piroxicam, 20 mg once daily11525 months5 months39Mean age 53 years33% malesDavatchi 2009 \[[@CR21]\]IranBehcet's diseaseColchicine, 1 mg dailyPlacebo11224 months4 months282Mean age 32.1 years32% malesDeftereos 2013 \[[@CR22]\]GreeceBare-metal stent restenosis in people with diabetesColchicine, 0.5 mg twice dailyPlacebo11826 months6 months222Mean age 63.6 years65% malesDemidowich 2019 \[[@CR23]\]USAMetabolic syndromeColchicine, 0.6 mg twice dailyPlacebo1.236.63 months3 months40Mean age 45.8 years23% malesDinarello 1974 \[[@CR12]\]USAFamilial Mediterranean feverColchicine, 0.6 mg 3 times dailyPlacebo1.8602.311 months11 months11Mean age NR% males NRFish 1997 \[[@CR24]\]USAAsthmaColchicine, 0.6 mg twice dailyPlacebo1.250.46 weeks6 weeks71Mean age 34 years48% malesImazio 2010 \[[@CR25]\]ItalyPost-periocardiotomy syndromeColchicine, 1 mg daily for first day then 0.5 mg daily for 1 month (\<  70 kg) or 1 mg twice daily for first day then 0.5 mg twice daily for 1 month (≥70 kg)Placebo0.5 to 115 to 301 month1 month360Mean age 66 years66% malesImazio 2011 \[[@CR26]\]ItalyRecurrent pericarditisColchicine, 1 mg daily for first day then 0.5 mg daily for 1 month (\< 70 kg) or 1 mg twice daily for first day then 0.5 mg twice daily for 1 month (≥ 70 kg)Placebo0.5 to 191 to 1826 months18 months120Mean age 47.6 years53% malesImazio 2013 \[[@CR27]\]ItalyAcute pericarditisColchicine, 0.5 mg daily (\< 70 kg) or 0.5 mg twice daily (≥ 70 kg)Placebo0.5 to 1.046 to 913 months22 months (mean)240Mean age 52.1 years60% malesImazio 2014a \[[@CR28]\]ItalyPost-periocardiotomy syndrome and postoperative atrial fibrillationColchicine, 0.5 mg daily (\<  70 kg) or 0.5 mg twice daily (≥ 70 kg)Placebo0.5 to 1.015 to 301 month3 months360Mean age 67.5 years69% malesImazio 2014b \[[@CR29]\]ItalyPericarditisColchicine, 0.5 mg daily (\<  70 kg) or 0.5 mg twice daily (≥ 70 kg)Placebo0.5 to 1.091 to 1826 months18 months240Mean age 48.7 years50% malesKaplan 1986 \[[@CR6]\]USAPrimary biliary cirrhosisColchicine, 0.6 mg twice dailyPlacebo1.2876.024 months24 months60Mean age NR5% malesKershenobich 1979 \[[@CR9]\]MexicoCirrhosisColchicine, 1 mg daily, 5 days/weekPlacebo0.7141042.448 months48 months43Mean age 55.6 years58% malesKershenobich 1988 \[[@CR10]\]MexicoCirrhosisColchicine, 1 mg daily, 5 days/weekPlacebo0.7141224.914 years (mean 4.7 years)14 years (mean 4.7 years)100Mean age 50.3 years49% malesLeung 2018 \[[@CR30]\]SingaporeKnee osteoarthritisColchicine, 0.5 mg twice dailyPlacebo111216 weeks16 weeks109Mean age 58.5 years29% malesLiebenburg 2016 \[[@CR31]\]South AfricaTuberculous pericarditisColchicine, 1 mg dailyPlacebo1426 weeks6 weeks33Mean age 31 years33% malesMasuda 1989 \[[@CR32]\]JapanBehcet's diseaseColchicine, 1 mg dailyCyclosporin, 10 mg/kg daily111216 weeks16 weeks96Mean age NR% males NRMcKendry 1993 \[[@CR13]\]CanadaPsoriatic arthritisColchicine, 0.6 mg daily for first week, 0.6 mg twice daily for second week, 0.6 mg 3 times daily for 6 weeksplacebo1.57588.28 weeks8 weeks25Mean age 40.7 years56% malesOlsson 1995 \[[@CR11]\]SwedenPrimary sclerosing cholangitisColchicine, 1 mg dailyplacebo1109536 months36 months84Mean age 41.6 years67% malesPakfetrat 2010 \[[@CR33]\]IranRecurrent aphthous stomatitisColchicine, 0.5 mg dailyPrednisolone, 5 mg/d daily0.5473 months6 months34Mean age 31.5 years35% malesPaulus 1974 \[[@CR34]\]USAGoutColchicine, 0.5 mg 3 times daily + probenecid 500 mg 3 times dailyProbenecid, 500 mg 3 times daily1.52746 months6 months52Mean age 52.5 years100% malesRoche 1995 \[[@CR14]\]FranceAllergic rhinitisColchicine, 1 mg twice daily for 3 days then once daily for 5 daysPlacebo1.375118 days8 days16Age range 20 to 30 years100% malesSchlesinger 2011 \[[@CR15]\]USAGoutColchicine, 0.5 mg dailyCanakinumab dose ranging: single dose of 25 mg, 50 mg, 100 mg,200 mg, 300 mg or four doses at four-weekly intervals (50 mg, 50 mg, 25 mg, 25 mg)0.55616 weeks24 weeks432Mean age 52.4 years94% malesSchnebel 1988 \[[@CR35]\]USALow back painColchicine, 0.6 mg hourly for 8 h then 0.6 mg every fourth dayPlacebo2.1191.63 months3 months34Mean age 69.1 years63% malesSeideman 1987 \[[@CR36]\]SwedenPsoriatic arthritisColchicine, 0.5 mg up to 3 times daily increased over 6 daysPlacebo0.5 to 1.530 to 912 months2 months15Age range 20 to 65 years% males NRTardif 2019 \[[@CR37]\]CanadaMyocardial InfarctionColchicine, 0.5 mg dailyPlacebo0.5640.542 months42 months4745Mean age 60.6 years81% malesTerkeltaub 2010 \[[@CR38]\]USAGoutColchicine, 1.2 mg followed by 0.6 mg in 1 h (low dose) or 1.2 mg followed by 0.6 mg hourly for 6 h (high dose)Placebo1.8 to 4.81.8 to 4.81--6 h7 days185Mean age 51.5 years95% malesWang 2014 \[[@CR39]\]ChinaGoutColchicine, 0.5 mg twice daily for 3 days then once dailyChuanhu anti-gout mixture, 250 ml daily0.656.510 days13.4 weeks176Mean age 52.8 years94% malesYurdakul 2001 \[[@CR40]\]TurkeyBehcet's syndromeColchicine, 0.5 mg twice daily (≤50 kg), 0.5 mg alternating twice and 3 times daily (50--49 kg), 0.5 mg 3 times daily (60--75 kg), 0.5 mg alternating 3 and 3 times daily (76--84 kg), 0.5 mg 4 times daily (≥ 85 kg)Placebo1 to 2730 to 146024 months24 months116Mean age 27 years52% males*NR* Not reported

Intervention characteristics {#Sec11}
----------------------------

Of the 8659 pooled participants, 4225 participants were randomised to receive colchicine, 3956 to the placebo and 411 to an active comparator. The remaining 67 participants were included in cross-over trials and received both colchicine and placebo treatments over the duration of the study \[[@CR12]--[@CR15]\].

The length of treatment varied across studies (Table [1](#Tab1){ref-type="table"})). The majority of studies administered treatment for ≥ 1 to ≤ 6 months (*n* = 16 studies) \[[@CR13], [@CR15], [@CR16], [@CR20], [@CR21], [@CR23]--[@CR25], [@CR27], [@CR28], [@CR30]--[@CR33], [@CR35], [@CR36]\], \> 6 to ≤ 12 months (*n* = 6 studies) \[[@CR12], [@CR18], [@CR22], [@CR26], [@CR29], [@CR34]\] or \> 12 to ≤ 48 months (*n* = 6 studies) \[[@CR6], [@CR8], [@CR9], [@CR11], [@CR37], [@CR40]\]. Four studies administered treatment for one to 2 weeks \[[@CR14], [@CR17], [@CR19], [@CR39]\] and participants in one study received treatment for one to 6 h \[[@CR38]\]. Participants in two studies received treatment for ≥ 10 years \[[@CR7], [@CR10]\]. The mean daily dose of colchicine ranged from 0.5 mg to 4.8 mg. One study \[[@CR38]\] reported the difference in the number of participants with adverse events based on whether they received low dose colchicine (total dose 1.8 mg) or high dose colchicine (total dose 4.8 mg).

Adverse events {#Sec12}
--------------

Methods used in the included studies to assess adverse events are described in Supplementary Table [1](#MOESM1){ref-type="media"}. Assessment methods included self-reporting of symptoms by patients, questioning of adverse events by investigators during study visits and undertaking blood tests and laboratory analyses.

### Any adverse event {#Sec13}

The number of participants with any adverse event was reported by 27 papers ([Supplementary Table 2](#MOESM1){ref-type="media"}). From this data, 21.1% (95% confidence interval (CI) 19.9, 22.4) of participants using colchicine reported any adverse event compared to 18.9% (95% CI 17.7, 20.1) of participants in comparator groups. A meta-analysis showed the overall estimated risk ratio (RR) (95% CI) of any adverse event in colchicine users compared with pooled comparator groups was 1.46 (1.20, 1.77), *P* \< 0.001 (Fig. [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). The difference in RR of any adverse event in colchicine users was not significantly different between placebo and active comparator groups (*P* = 0.27). After the exclusion of six studies involving participants with liver disease, the RR (95% CI) of any adverse event in colchicine users vs. comparator groups was similar at 1.37 (1.14, 1.65), *P* \< 0.001 ([Supplementary Table 3](#MOESM1){ref-type="media"}). Fig. 2Forest plot showing estimated relative risk of any adverse event during colchicine use compared to placebo and active comparator groups Table 2Meta-analysis results showing pooled risk ratio of adverse events between colchicine and pooled comparator groups*N*. studies*n*/*N*, % (95% CI) participantsPooled risk ratio (95% CI)*I*^2^ (*P* value)Overall effect, *Z* (*P* value)^a^ColchicineComparatorAny event27845/4007, 21.1% (19.9, 22.4)784/4152, 18.9% (17.7, 20.1)1.46 (1.20, 1.77)58% (\< **0.001**)3.82 (\< **0.001**)Diarrhoea19420/3212, 17.9% (16.8, 19.1)262/3142, 13.1% (11.9, 14.3)2.44 (1.62, 3.69)58% (**\< 0.001**)4.24 (**\< 0.001**)Gastrointestinal^b^29729/4131, 17.6% (16.5, 18.8)552/4213, 13.1% (12.1, 14.2)1.74 (1.32, 2.30)53% (**\< 0.001**)3.94 (**\< 0.001**)Liver1322/1150, 1.9% (1.2, 2.8)15/1362, 1.1% (0.6, 1.8)1.61 (0.86, 3.02)0% (0.48)1.50 (0.13)Muscle^c^937/872, 4.2% (3.0, 5.7)29/869, 3.3% (2.3, 4.7)1.25 (0.80, 1.93)0% (0.69)0.98 (0.33)Haematology816/2878, 0.6% (0.3, 0.9)12/2893 0.4% (0.2, 0.7)1.34 (0.64, 2.82)0% (0.69)0.77 (0.44)Sensory^d^23/201, 1.5% (0.4, 4.0)2/190, 1.1% (0.2, 3.4)1.35 (0.27, 6.74)0% (0.58)0.37 (0.71)Infectious7105/2763, 3.8% (3.1, 4.6)131/2997, 4.4% (3.7, 5.1)1.03 (0.70, 1.51)46% (0.09)0.13 (0.90)^a^Bolded *P* values indicate a significant overall effect in the risk ratio for an adverse event between colchicine and comparator groups^b^The gastrointestinal category includes diarrhoea^c^The muscle category includes myalgia, muscle cramps, myotoxicity, muscle weakness and elevated CPK. No rhabdomyolysis was assessed or reported by any study^d^The sensory category includes dysthesia and paresthesia. No neuropathy was assessed or reported by any study

Although the sub-group meta-analyses showed a higher relative risk for any adverse event in colchicine users with liver diseases (RR 5.92 (95% CI 2.08, 16.82)), there was no overall significant difference in the relative risk of adverse events between different disease indications (*P* = 0.11) (Fig. [3](#Fig3){ref-type="fig"}). Furthermore, there was no significant difference in relative risk across different durations of drug exposure (*P* = 0.29) ([Supplementary Figure 2](#MOESM1){ref-type="media"}), different colchicine daily dose categories (*P* = 0.70) ([Supplementary Figure 3](#MOESM1){ref-type="media"}) or different colchicine cumulative dose categories (*P* = 0.09) (Fig. [4](#Fig4){ref-type="fig"}). Fig. 3Forest plot showing estimated relative risk of any adverse event during colchicine use compared to comparator groups across different disease indications Fig. 4Forest plot showing estimated relative risk of any adverse event during colchicine use compared to comparator groups across different cumulative doses of colchicine

The proportion of participants with any adverse event computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 20.6% (95% CI 19.5, 21.9) in colchicine users and 17.9% (95% CI 16.8, 19.1) in comparator groups.

### Diarrhoea {#Sec14}

The number of participants with diarrhoea was reported by a total of 19 papers ([Supplementary Table 2](#MOESM1){ref-type="media"}). From this data, 17.9% (95% CI 16.8 19.1) of participants using colchicine reported diarrhoea compared to 13.1% (95% CI 11.9, 14.3) of participants in comparator groups. The meta-analysis showed the overall estimated RR (95% CI) of diarrhoea in colchicine users compared with pooled comparator groups was 2.44 (1.62, 3.69) (*P* \< 0.001) (([Supplementary Figure 4](#MOESM1){ref-type="media"}, Table [2](#Tab2){ref-type="table"}). The difference in RR between placebo and active comparator groups was not significant (*P* = 0.60). After exclusion of 6 studies involving participants with liver disease the RR (95% CI) of diarrhoea in colchicine users vs comparator groups was similar at 2.14 (1.40, 3.26), *P* \< 0.001 ([Supplementary Table 3](#MOESM1){ref-type="media"}).

The proportion of participants with diarrhoea computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 10.8% (95% CI 9.9, 11.7) in colchicine users and 6.1% (95% CI 5.4, 6.8) in comparator groups.

### Gastrointestinal adverse event {#Sec15}

The number of participants with any gastrointestinal event was reported by 29 papers ([Supplementary Table 2](#MOESM1){ref-type="media"}) and included diarrhoea, nausea, vomiting, abdominal pain, loss of appetite, bloating, constipation, melena and peptic ulcer ([Supplementary Table 4](#MOESM1){ref-type="media"}). From these 29 papers, 17.6% (95% CI 16.5, 18.8) of participants using colchicine reported a gastrointestinal event compared to 13.1% (95% CI 12.1, 14.2) of participants in comparator groups. The overall RR (95% CI) of gastrointestinal events in colchicine users compared with pooled comparator groups was 1.74 (1.32, 2.30), *P* \< 0.001 (Fig. [5](#Fig5){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). The difference between placebo and active comparator groups was not significant (*P* = 0.32). After the exclusion of 6 studies involving participants with liver disease, the RR (95% CI) of any gastrointestinal event in colchicine users vs comparator groups was similar at 1.60 (1.22, 2.10), *P* \< 0.001 ([Supplementary Table 3](#MOESM1){ref-type="media"}). Fig. 5Forest plot showing estimated relative risk of any gastrointestinal event during colchicine use compared to placebo and active comparator groups

The proportion of participants with any gastrointestinal event computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 17.7% (95% CI 16.6, 18.8) in colchicine users and 12.6% (95% CI 11.6, 13.6) in comparator groups.

### Liver events {#Sec16}

The number of participants with liver events was reported by 13 papers ([Supplementary Table 2](#MOESM1){ref-type="media"}) and included increased liver enzymes, hepatitis, hepatotoxicity and hepatic abnormalities ([Supplementary Table 4](#MOESM1){ref-type="media"}). Pooled data from these papers showed 1.9% (95% CI 1.2, 2.8) of participants using colchicine reported a liver event compared to 1.1% (95% CI 0.6, 1.8) of participants in comparator groups. The overall RR (95% CI) of liver events in colchicine users did not significantly differ from the pooled comparator groups: 1.61 (0.86, 3.02) ([Supplementary Figure 5](#MOESM1){ref-type="media"}, Table [2](#Tab2){ref-type="table"}). The difference between placebo and active comparator groups was also not significant. None of the included papers involved participants with liver diseases.

The proportion of participants with any liver event computed from all 32 studies in this review (in which prevalence was considered 0% if not reported) was 0.5% (95% CI 0.3, 0.7) in colchicine users and 0.3% (95% CI 0.2, 0.5) in comparator groups.

### Muscle events {#Sec17}

The number of participants with muscle events was reported by nine studies ([Supplementary Table 2](#MOESM1){ref-type="media"}) and included myalgia, muscle cramps, elevated creatine phosphokinase and muscle weakness ([Supplementary Table 5](#MOESM1){ref-type="media"}). Rhabdomyolysis was not mentioned in any study. All nine studies involved placebo comparator groups. Pooled data from these studies showed 4.2% (95% CI 3.0, 5.7) of participants using colchicine reported a muscle event compared to 3.3% (95% CI 2.3, 4.7) of participants in placebo groups. The meta-analysis showed an overall non-significant RR (95% CI) of muscle events in colchicine users of 1.25 (0.80, 1.93) (Fig. [6](#Fig6){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). None of the studies involved participants with liver diseases. Fig. 6Forest plot showing estimated relative risk of muscle events during colchicine use compared to placebo (no active comparator studies)

The proportion of participants with muscle events computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 0.8% (95% CI 0.6, 1.1) in colchicine users and 0.6% (95% CI 0.4, 0.9) in comparator groups.

### Haematology events {#Sec18}

The number of participants with haematology events was reported by eight studies ([Supplementary Table 2](#MOESM1){ref-type="media"}) and included anaemia, bone marrow toxicity, leukopenia and purpura ([Supplementary Table 4](#MOESM1){ref-type="media"}). All studies involved placebo comparator groups. Pooled data from these studies showed 0.6% (95% CI 0.3, 0.9) of participants using colchicine reported a haematology event compared to 0.4% (95% CI 0.2, 0.7) of participants in placebo groups. The occurrence of haematology events in colchicine or comparator groups was reported by three studies \[[@CR21], [@CR23], [@CR37]\]. The meta-analysis showed an overall non-significant RR (95% CI) of haematology events in 1.34 (0.64, 2.82) ([Supplementary Figure 6](#MOESM1){ref-type="media"}, Table [2](#Tab2){ref-type="table"}). None of the studies involved participants with liver diseases.

The proportion of participants with a haematology event computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 0.4% (95% CI 0.2, 0.6) in colchicine users and 0.3% (95% CI 0.1, 0.4) in comparator groups.

### Sensory events {#Sec19}

No studies mentioned neuropathy-related adverse events. However, two studies involving placebo comparator groups reported other sensory events ([Supplementary Table 2](#MOESM1){ref-type="media"}) which included dysthesia in the legs and paresthesia ([Supplementary Table 5](#MOESM1){ref-type="media"}). From this data, the pooled prevalence of sensory events was 1.1% (95% CI 0.2, 3.4) in colchicine users and 1.5% (95% CI 0.4, 4.0) in placebo groups. The meta-analysis showed an overall non-significant RR (95% CI) of sensory events in colchicine users of 1.35 (0.27, 6.74) ([Supplementary Figure 7](#MOESM1){ref-type="media"}, Table [2](#Tab2){ref-type="table"}). None of the included papers involved participants with liver diseases.

The proportion of participants with any sensory events computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 0.04% (95% CI 0.0, 0.1) in colchicine users and 0.07% (95% CI 0.0, 0.2) in comparator groups.

### Infectious events {#Sec20}

Seven studies reported various infectious events ([Supplementary Table 2](#MOESM1){ref-type="media"}), including urinary tract infection, parotiditis, shingles, upper respiratory tract infection, nasopharyngitis and sinus congestion ([Supplementary Table 5](#MOESM1){ref-type="media"}). From these papers, 0.4% (95% CI 0.2, 0.6) of participants using colchicine reported an infectious event compared to 2.1% (95% CI 1.6, 2.7) of participants in comparator groups. The overall RR (95% CI) of infectious events in colchicine users compared with pooled comparator groups was non-significant: 1.03 (0.70, 1.51) ([Supplementary Figure 8](#MOESM1){ref-type="media"}, Table 2). The difference between placebo and active comparator groups was not significant (*P* = 0.94). No study involved participants with liver diseases.

The proportion of participants with any infectious event computed from all 35 studies in this review (in which prevalence was considered 0% if not reported) was 2.4% (95% CI 2.0, 2.9) in colchicine users and 2.8% (95% CI 2.4, 3.4) in comparator groups.

### Death {#Sec21}

Death related to adverse events was specifically reported in three studies ([Supplementary Table 2](#MOESM1){ref-type="media"}). No study reported deaths related to an adverse event.

### Miscellaneous events {#Sec22}

Miscellaneous adverse events reported by the included studies are summarised in [Supplementary Table 6](#MOESM1){ref-type="media"}. These events were not meta-analysed but contributed to the 'any adverse event' category.

Discussion {#Sec23}
==========

This systematic review and meta-analysis of randomised controlled trials indicate that overall, colchicine increases the rate of adverse events compared to both placebo and active comparators. Analysis of individual events demonstrated an increased risk for diarrhoea and gastrointestinal events in colchicine users, but no increase in the rate of other commonly cited adverse events, including liver, muscle, haematology, sensory or infectious events.

The mechanism by which colchicine induces diarrhoea and other gastrointestinal symptoms is not exactly known, but can be attributed to an increase in prostaglandin synthesis, intestinal secretion and gastrointestinal motility with this drug \[[@CR41]\]. Although these symptoms can be clinical features of colchicine toxicity, they are usually mild, short-lived and reversible with dose reduction \[[@CR12]\]. Serious adverse events associated with colchicine use, including neuropathy, myotoxicity and death were not reported in any trial included in the current analysis. These events may be more readily observed in less controlled environments evident in case reports involving colchicine over-dose, chronic renal diseases, interaction with concomitant medications and intravenous administration \[[@CR42]--[@CR49]\].

Analysis of adverse events in colchicine users showed no difference across different disease indications. Although overall, adverse events were numerically higher in patients with liver diseases, this risk was not significantly different from other disease indications. Furthermore, the sub-analysis excluding participants with liver disease showed similar adverse events rates to the main analysis. Although dose reduction is generally recommended when colchicine is used continuously in those with severe renal impairment, accurate conclusions regarding adverse events in this population could not be drawn from the current analysis.

There was notable heterogeneity across the clinical trials included in this review with regards to intervention methodology, including colchicine dose and treatment duration. However, sub-group analyses concluded that differences in drug use duration, daily dose or cumulative dose categories had no effect on the risk for adverse events. This contrasts with trials assessing the treatment of acute gout which report that high-dose colchicine results in a greater risk-to-benefit ratio. The paper reporting the AGREE trial included in the current analysis by Terkeltaub et al. \[[@CR38]\], which directly compared two different doses of colchicine, found differences in adverse event rates between low and high dose groups, with 36% and 81% of participants having any adverse event, respectively. However, the short duration of treatment (1 to 6 h) meant that the cumulative drug doses in both groups were low in the context of the other papers included in the meta-analysis, resulting in a non-significant effect of dose in the meta-analysis. The difference in adverse event rates between the two arms of this AGREE trial may relate to better surveillance of adverse events in this trial compared to previously reported trials, or the relatively high dose (4.8 mg over 6 h) of the high-dose colchicine group. This is the only published trial comparing two differing doses of colchicine so conclusions on the reason for this disparity are difficult to be definitive about.

The limitations of this study include the inability in assessing the occurrence of rarer adverse events when only short duration controlled clinical trials were included. Different methodology is required to assess the frequency of rarer adverse events. Furthermore, the aims of the majority of the included studies were not primarily to assess safety, resulting in limited availability of adverse event data for extraction. As only studies which specifically reported an adverse event as being present or absent were included in the meta-analyses, it is possible that the pooled results may have over-estimated the true occurrence of adverse events which were not reported in all papers. In addition, it is also possible that the pooled results may have under-estimated the true occurrence of adverse events which were not assessed (e.g. those requiring blood tests). There were few included participants with severely impaired renal function, so the ability to assess for safety in this group was limited. Clinical trials often recruit patients in a highly selective manner, including excluding those with co-morbidities, and therefore the results are not necessarily generalizable to a general patient population. In addition, the included studies spanned over 20 years and it is likely that participants in earlier studies are not representative of patients treated with colchicine in clinical practice today. Other limitations include the screening of titles, abstracts and full-texts being undertaken by a single reviewer, and the exclusion of non-English language publications.

The strengths of this study include the strict inclusion of only placebo or active comparator blinded trials which reduces the potential for bias; although the occurrence of diarrhoea in participants can lead to at the least the suspicion of being in the colchicine group. In addition, there was a wide range of included indications such as gout, familial Mediterranean fever, Behcet's disease and pericarditis, which leads to increased generalisability of the study results.

Conclusions {#Sec24}
===========

This meta-analysis provides reassurance that common adverse events with colchicine use are limited to diarrhoea and gastrointestinal events. Whilst these are not benign side effects in some individuals, they will settle on dose reduction or drug discontinuation. More serious adverse events during colchicine use, including liver and haematological changes, muscle toxicity, neuropathy and death are very infrequent in clinical trials.

Supplementary information
=========================

 {#Sec25}

**Supplementary Table 1.** Participant inclusion and exclusion criteria and adverse event assessment methods of included studies. Table 2. Frequency of any adverse event reported in colchicine and comparator groups. Table 3. Meta-analysis results showing pooled risk ratio of adverse events between colchicine and pooled comparator groups for studies not involving participants with liver diseases. Table 4. Number of participants in colchicine and comparator groups with adverse events related to gastrointestinal, liver and hematologic events. Table 5. Number of participants in colchicine and comparator groups with adverse events related to muscle, sensory, and infectious events. Table 6. Number of participants in colchicine and comparator groups with miscellaneous adverse events or death. Figure 1. Quality assessment results using the modified-Jadad score. Figure 2. Forest plot showing estimated relative risk of any adverse event during colchicine use compared to comparator groups across different durations of drug exposure. Figure 3. Forest plot showing estimated relative risk of any adverse event during colchicine use compared to comparator groups across different daily doses of colchicine. Figure 4. Forest plot showing estimated relative risk of diarrhoea during colchicine use compared to placebo and active comparator groups. Figure 5. Forest plot showing estimated relative risk of liver events during colchicine use compared to placebo and active comparator groups. Figure 6. Forest plot showing estimated relative risk of hematology events during colchicine use compared to placebo (no active comparator studies). Figure 7. Forest plot showing estimated relative risk of sensory events during colchicine use compared to placebo (no active comparator studies). Figure 8. Forest plot showing estimated relative risk of infectious events during colchicine use compared to placebo and active comparator groups.
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